Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG

NCT04162600 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
18
Enrollment
OTHER
Sponsor class

Stopped Since acceptable safety, tolerability, and immunogenicity was demonstrated at the highest dose tested (group 3, fully recruited), there was no scientific or ethical justification to recruit more participants into the mid-dose group (group 2).

Conditions

Interventions

Sponsor

University of Oxford